Antibacterial Drugs Market will grow at 0.7% CAGR, to be valued at US$ 44,063.3 Mn by 2028 | Global Industry Analysis by Company Profiles, Segments, Size, Landscape and Demand

Antibacterial drugs are widely used to treat and prevent infectious diseases and are categorized into seven major classes, such as β-Lactams, phenicols, macrolides, quinolones, sulfonamides, tetracyclines, and aminoglycosides, based on their molecular structure. Antibacterial drugs destroy or slow down the growth of bacteria. These medications are also used to treat urinary infections caused by S. aureus, E. coli, Streptococcus pyogenes, and other bacterial infections.

The PDF for the study can be requested using the following link: https://www.coherentmarketinsights.com/insight/request-pdf/177

They include a range of powerful drugs used to treat diseases caused by bacteria. Antibiotics cannot treat viral infections, such as cold, flu, and most coughs. Antibacterial drugs play a major role in advanced healthcare, as they are widely used to treat infectious diseases, such as tuberculosis, malaria, typhoid, leprosy, hepatitis B, HIV/AIDS, and others. Thus, there is an increasing demand for antibacterial drugs worldwide.

Competitive Landscape:

Major players operating in the global antibacterial drugs market are Sanofi, Pfizer, Novartis, Merck & Co., Johnson & Johnson, Forest Laboratories, Eli Lilly and Company, Bayer AG, AstraZeneca plc, GlaxoSmithKline, Spero Therapeutics, VenatoRx Pharmaceuticals, NacuGen Therapeutics, Sichuan Pharmaceutical, Boston Pharmaceuticals, Debiopharm Group, Micurx Pharmaceutical Inc., Melinta Therapeutics, Entasis Therapeutics, R-Pharm Group, Theravance Biopharma, TenNor Therapeutics, Allecra Therapeutics GmbH, Kyorin Pharmaceutical Co., Iterum Therapeutics plc, Shionogi Inc, Wockhardt, and Bristol-Myers Squibb Company.

Key Market Drivers:

Increasing prevalence of infectious diseases around the world is expected to boost the growth of the antibacterial drugs market over the forecast period. Worldwide, tuberculosis is one of the top ten causes of death. For instance, according to the World Health Organization (WHO), in 2019, around 10 million people fell ill with tuberculosis worldwide. Tuberculosis is present in all countries and age groups.

Moreover, increasing incidences of bacterial infections worldwide is expected to drive growth of the antibacterial drugs market. For instance, according to the Centers for Disease Control and Prevention (CDC), each year, more than 2.8 million antibiotic-resistant infections occur in the United States, and more than 35,000 people die as a result.

COVID-19 Impact Analysis:

The pandemic had a temporary or minimal impact on the antibiotics and antimicrobials market or its growth during the forecast period. On the other hand, worldwide, there was high demand for antimicrobial drugs during the pandemic, such as cefuroxime, meropenem, vancomycin, cefepime, ceftazidime, ciprofloxacin, piperacillin/tazobactam, benzylpenicillin, gentamicin, ampicillin, amoxicillin, erythromycin, ceftriaxone, clarithromycin, doxycycline, azithromycin, and amoxicillin-clavulanic acid, among others.
These antimicrobials were recommended for use in the management of COVID-19. Moreover, pharmaceutical companies responded to the growing demand for antibiotics and other essential medicines for patients during COVID-19. This in turn is expected to augment the growth of the antibacterial drugs market.

Key Takeaways

• The antibacterial drugs market is expected to exhibit a CAGR of XX % during the forecast period owing to the increasing launches and approvals of new antibacterial drugs across the world. For instance, in June 2020, the U.S. Food and Drug Administration (FDA) approved Recarbrio (antibacterial drug) to treat hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia (HABP/VABP) in patients 18 years of age and older.
• Among regions, North America is expected to witness robust growth in the antibacterial drugs market due to the increasing incidences of infectious diseases, such as tuberculosis, salmonella, Lyme disease, and meningococcal disease, in the region, especially in the U.S. According to CDC, in 2018, around 9,025 new cases of tuberculosis, 60,999 new cases of salmonella, 33,666 new cases of Lyme disease, and 327 cases of meningococcal disease were reported in the United States.

Buy This Research Study Report For Quick Access@ https://www.coherentmarketinsights.com/insight/buy-now/177

Contact Us

Mr. Shah
Coherent Market Insights
1001 4th Ave, #3200
Seattle, WA 98154
Phone: US +12067016702 / UK +4402081334027
Email: sales@coherentmarketinsights.com

About Coherent Market Insights

Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

This release was published on openPR.